Benaim Ely's Form 4 filing
NovoCure Ltd (NVCR) · filed May 12, 2022
- Accession no.
- 0001645113-22-000046
- Filed
- May 12, 2022
- Trade date
- May 10-11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $265.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Benaim ElyCIK 0001632237 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 10, 2022 | Ordinary Shares | SSaleDisposed | −2,070 | $65.16 | −$134,881.2 | 36,981 | Direct | |
| May 11, 2022 | Ordinary Shares | SSaleDisposed | −2,135 | $61.25 | −$130,768.75 | 34,846 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.